Australian Investment Blog

ASX:CSL 15/08/2018

CSL – shareholders get another injection

Stock

CSL $211.80 as at 15/08/2018

Event

Biotech company CSL once again impressed investors at the full year result this morning, showing another solid year of growth with net profit rising 29%, lifting the dividend 30%. New launches as well as now fully integrated acquisitions contributed to the blood products and vaccines businesses result. Raising questions such as, is CSL a buy?

The market didn’t seem to mind a slightly soft guidance with the company known for under promising the year ahead. For the financial year just gone, CSL upgraded guidance twice – the last in march – and still beat the updated numbers. Consensus NPAT was looking for $1,969m in FY19, while the company guided to $1,880 - $1950m, about a 2.7% miss. CSL Chart

Is CSL a buy now?

It has run strongly, and currency tailwinds along with improving business conditions will continue to help CSL. It does trade on a high multiple which is why we remain cautious, looking for a pullback towards $180 to be more interested.

Subscribe to Market Matters Blog

Latest Reports

Weekend report 04/10/2025

Weekend Q&A: The ASX is on track for new all-time highs this week

The ASX200 ended last week up +2.3%, with the first three days of October already recouping all of September's decline. The healthcare sector made a welcome return to the winners' enclosure, ably supported by the influential miners and banks, while the energy sector was the only meaningful drag on the index. Only a flat week by the heavyweight iron ore miners reined in performance, although their sector peers worked hard to address their slumber, with 18 members of the materials sector closing out the week up more than +5%.

Afternoon report 03/10/2025

The Match Out: ASX finishes the week strong, APE jumps on CanadaOne acquisition

The ASX finished the week strongly, rising steadily through the session with strength in healthcare, tech and consumer names more than offsetting softer trade in energy and utilities.